Table 1 Baseline patient characteristics, PCI profile, and discharge medications
Variables | mean ± SD, n (%), median (MIN–MAX) n = 134 | Missing value (%) | ||
|---|---|---|---|---|
Age (years) | 76.0 | ± 6.2 | 0.0 | |
Sex (male) | 111 | (82.8) | 0.0 | |
Body weight (kg) | 60.53 | ± 10.69 | 0.0 | |
Body mass index (kg/m2) | 22.83 | ± 3.00 | 0.0 | |
Smoking history | 83 | (61.9) | 0.0 | |
Alcohol consumption history | 62 | (46.6) | 0.7 | |
Heart rate (times/min) | 73.9 | ± 19.0 | 0.0 | |
Systolic blood pressure (mmHg) | 120.5 | ± 22.0 | 0.0 | |
Diastolic blood pressure (mmHg) | 68.5 | ± 13.8 | 0.0 | |
History of surgery | 22 | (16.4) | 0.0 | |
History of bleeding | 19 | (14.2) | 0.0 | |
History of CABG | 6 | (4.5) | 0.0 | |
Concomitant disease or medical history | ||||
Hypertension | 101 | (75.4) | 0.0 | |
Dyslipidemia | 71 | (53.0) | 0.0 | |
Diabetes mellitus | 46 | (34.3) | 0.0 | |
Cerebral infarction | 25 | (18.7) | 0.0 | |
Myocardial infarction | 16 | (11.9) | 0.0 | |
Heart failure | 55 | (41.0) | 0.0 | |
Malignancy | 25 | (18.7) | 0.0 | |
Dialysis | 5 | (3.7) | 0.0 | |
Liver disease | 8 | (6.0) | 0.0 | |
Anemia | 30 | (22.4) | 0.0 | |
Gastrointestinal disease | 30 | (22.4) | 0.0 | |
Peripheral arterial disease | 16 | (11.9) | 0.0 | |
PCI profile | ||||
Number of target lesions | 1.4 | ± 0.6 | 0.0 | |
Lesion site | 0.0 | |||
Right coronary artery | 31 | (23.1) | 0.0 | |
Left main trunk | 5 | (3.7) | 0.0 | |
Left anterior descending coronary artery | 76 | (56.7) | 0.0 | |
Left circumflex coronary artery | 22 | (16.4) | 0.0 | |
Chronic total occlusion | 33 | (24.6) | 0.0 | |
Multivessel disease | 69 | (51.5) | 0.0 | |
Stent type | 0.0 | |||
Bare metal stent | 24 | (17.9) | 0.0 | |
Drug eluting stent | 110 | (82.1) | 0.0 | |
Clinical presentation | 0.0 | |||
Acute coronary syndrome | 63 | (47.0) | 0.0 | |
Stable coronary artery diseases | 71 | (53.0) | 0.0 | |
Laboratory data | ||||
Albumin (g/dL) | 3.7 | ± 0.5 | 0.0 | |
White blood cell (/µL) | 6400.0 | (3300–19950) | 0.0 | |
Hemoglobin (g/dL) | 12.80 | ± 1.97 | 0.0 | |
Platelet (104/µL) | 19.84 | ± 6.46 | 0.0 | |
Aspartate aminotransferase (U/L) | 27.5 | (13–501) | 0.0 | |
Alanine aminotransferase (U/L) | 22.0 | (4–449) | 0.0 | |
eGFR (mL/min/1.73 m2) | 56.61 | ± 19.22 | 0.0 | |
Creatinine kinase (IU/L) | 94.0 | (17–5261) | 0.7 | |
C-reactive protein (mg/L) | 0.34 | (0.03–17.00) | 12.7 | |
Brain natriuretic peptide (pg/mL) | 246.80 | (14.4–3520.2) | 6.7 | |
PT-INR | 1.23 | ± 0.35 | 9.0 | |
Hemoglobin-A1c (NGSP %) | 6.42 | ± 1.07 | 21.6 | |
High-density lipoprotein (mg/dL) | 50.4 | ± 14.6 | 9.7 | |
Low-density lipoprotein (mg/dL) | 103.4 | ± 29.1 | 12.7 | |
Triglyceride (mg/dL) | 91.7 | ± 56.1 | 11.9 | |
Left ventricular ejection fraction (%) | 50.5 | ± 13.7 | 3.0 | |
Duration of hospital stay (days) | 12.0 | (2–83) | 0.0 | |
Medication at discharge | ||||
Type of oral anticoagulants | 0.0 | |||
Vitamin K antagonist | 54 | (40.3) | 0.0 | |
Direct oral anticoagulant | 80 | (59.7) | 0.0 | |
Proton pump inhibitors | 114 | (85.1) | 0.0 | |
HMG-CoA reductase inhibitors | 86 | (64.2) | 0.0 | |
Nonsteroidal anti-inflammatory drugs | 10 | (7.5) | 0.0 | |
Eicosapentaenoic acids | 2 | (1.5) | 0.0 | |
P-glycoprotein inhibitors | 6 | (4.5) | 0.0 | |
Long-term use of glucocorticoids | 2 | (1.5) | 0.0 | |